Investigating how LINE-1 retrotransposons affect diseases and normal body functions using specialized antibodies.
Development of a novel model to study the effects of LINE-1 retrotransposons in disease and normal physiology using nanobodies
This study is looking at how certain genetic elements called LINE-1 can affect diseases like Alzheimer's and autism, and they're trying to create a new way to target these elements using tiny antibodies, which could help improve treatments for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mercer University Macon NIH-funded |
| Lab location | 1 site (Macon, United States) |
| Project ID | NIH-10953070 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of LINE-1 retrotransposons, which are genetic elements that can influence various diseases and normal physiological processes. The team aims to develop a new model using nanobodies, which are small antibodies, to specifically target and reduce the activity of LINE-1 proteins. By isolating these nanobodies, the researchers hope to gain insights into how LINE-1 contributes to conditions like Alzheimer's disease and autism, potentially leading to better treatment strategies. Patients may benefit from advancements in understanding and managing diseases linked to LINE-1 activity.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with conditions such as Alzheimer's disease, autism spectrum disorder, or other diseases where LINE-1 activity is implicated.
Not a fit: Patients with conditions unrelated to LINE-1 retrotransposons or those not diagnosed with the target diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic approaches for diseases associated with LINE-1 retrotransposons.
How similar studies have performed: While the approach of using nanobodies to study LINE-1 is innovative, similar methodologies have shown promise in other areas of genetic research.
Where this research is happening
Macon, United States
- Mercer University Macon — Macon, United States (Active)
Researchers
- Principal investigator: Cook, Pamela — Mercer University Macon
- Study coordinator: Cook, Pamela
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.